Abstract: Objective To investigate the efficacy of combination of ezetimibe and atorvastatin in treatment of patients with nonalcoholic fatty liver disease （NAFLD） complicated by coronary heart disease （CHD）. Methods 114 patients with NAFLD and CHD were recruited in our hospital between February 2014 and February 2016,and were randomly divided into the observation group and the control group with 57 cases in each group by a computer-generated numbers. The patients in the control group were given atorvastatin calcium,and those in the observation group were given combination of ezetimibe and atorvastatin therapy for six months. The left ventricular ejection fraction（LVEF）,left ventricular end-diastolic diameter（LVVED） and left ventricular posterior wall depth （LVPWd） were obtained by echocardiography,and serum interleukin -6（IL-6） and interleukin-10 （IL-10） were assayed by ELISA. Results At the end of six month observation,serum TC,TG and LDL-C levels were（4.3±1.6） mmol/L,（2.4±0.9） mmol/L and （2.8±1.1） mmol/L,respectively in the observation group, significantly lower than （5.1±1.7） mmol/L,（2.9±0.9） mmol/L and （3.3±1.2） mmol/L （P<0.05） in the control group,while serum HDL-C level was （1.3±0.5） mmol/L,significantly higher than （1.0±0.4） mmol/L（P<0.05） in the control group;serum ALT,AST and GGT levels decreased significantly in the observation（P<0.05）;the LVEF was（47.2±6.4）%,significantly higher than（42.8 ±5.8）% （P<0.05）,while LEVDD and LVPWd were（52.5±7.3） mm and（10.1±0.9） mm,significantly lower than （58.2±7.6） mm and （11.4±1.1） mm,respectively （P<0.05） in the control;serum levels of ADMA,hs-CRP and IL-6 were （2.8±0.4） μmol/L,（3.4±0.7） mg/L and （39.3±6.9） ng/L,significantly lower than （3.0±0.4） μmol/L,（3.9±0.7） mg/L and （45.9±8.4） ng/L （P<0.05） in the control and serum level of IL-10 was （28.7±8.6） ng/L,significantly higher than （22.3±5.4） ng/L（P<0.05） in the control group. Conclusion s Ezetimibe combined with atorvastatin could significantly decrease the serum lipid levels and improve liver functions in patients with NAFLD complicated by CHD,which might be related to the regulation of lipid metabolism and reduced levels of ADMA and serum inflammatory factors.

Key words: Nonalcoholic fatty liver disease, Coronary heart disease, Ezetimibe, Atorvastatin, Efficacy